Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL742117 | 0.98 | MAOB (0.53) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL4363956 | 0.85 | MAOB (0.57) | MAOBTSHRMAPK1TAAR1 | |
| SCHEMBL8319257 | 0.84 | MAOB (0.50) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL6297020 | 0.83 | MAOB (0.59) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL29415192 | 0.82 | MAOB (0.57) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL288669 | 0.82 | MAOB (0.57) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL13318421 | 0.82 | MAOB (0.57) | MAOBMAPTTSHRMAPK1GAA | |
| SCHEMBL8296534 | 0.82 | MAOB (0.57) | MAOBMAPTAPPCYP3A4ESR1 | |
| SCHEMBL4393909 | 0.81 | ALDH1A1 (0.41) | MAOBMAPTMAPK1GAAESR2 | |
| SCHEMBL23671876 | 0.80 | MAOB (0.55) | MAOBMAPTTSHRMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | RASCAL THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3478284-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of The University of California (US) | 2019-05-08 | — | — | EP | disclosed |
| CN-109661229-A | Compound and composition for treating cancer | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| WO-2018005678-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | WO | disclosed |
| US-8227390-B2 | Binder resin for friction material, binder resin composition for friction material, composite material for friction material containing the same, friction material and production method thereof | AKEBONO BRAKE INDUSTRY CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20090137434-A1 | BINDER RESIN FOR FRICTION MATERIAL, BINDER RESIN COMPOSITION FOR FRICTION MATERIAL, COMPOSITE MATERIAL FOR FRICTION MATERIAL CONTAINING THE SAME, FRICTION MATERIAL AND PRODUCTION METHOD THEREOF | AKEBONO BRAKE INDUSTRY CO., LTD (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1805163-A2 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA¬A|PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010544-A2 | 1, 1A, 5, 5A-TETRAHYDRO-3-THIA-CYCLOPROPA’A! PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | MAOB 2441/4885MAPT 4548/4885TSHR 4375/4885 |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | MAOB 2441/4885MAPT 4548/4885TSHR 4375/4885 |
| US-20080064740-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | MAOB 4403/4885MAPT 2356/4885TSHR 1323/4885 |
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | MAOB 1587/4885MAPT 4157/4885TSHR 2636/4885 |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | TP53, HCCS, CFTR | MAOB 2441/4885MAPT 4548/4885TSHR 4375/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | MAOB 1846/4885MAPT 4262/4885TSHR 4820/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | MAOB 2441/4885MAPT 4548/4885TSHR 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.